Pioneering Pain-free Solutions
We leverage the power of medical technology to develop transformative, accurate solutions that improve the quality of life.
We are on a mission to redefine the approach to testing and deliver pain-free, accessible solutions that drive transformative change and improve the quality of life.
Our Technology
Revolutionizing Drug Testing Through Fingerprint Sweat Analysis
Our innovative Intelligent Fingerprinting Drug Testing Solution detects commonly abused drugs via sweat from the fingertips. The system’s ease of use and portability make it a convenient solution for reliable drug screening and identification of potential misuse within the 16-24 hours before testing.
Fingerprint DRUG Testing
A Dignified Approach to Drug Testing
Our Intelligent Fingerprinting Drug Screening System tests fingertip sweat for recent drug use, including cannabis, cocaine, opiates, and methamphetamine. Samples are collected in less than one minute and results displayed in less than ten minutes.
Non-invasive Drug Monitoring
SmarTest® Sweat Drug Testing Patch
The SmarTest Patch is a discreet, wearable device that detects drug use through sweat over a 7 to 10-day period. Comfortable, tamper-evident, and water-resistant, it’s ideal for longer-term monitoring in justice and rehabilitation settings.
Used alongside our Intelligent Fingerprinting Drug Screening System, it offers a complete non-invasive sweat-based solution for both immediate and continuous drug detection.
INVESTOR RELATIONS
Transforming Testing Solutions Through Med Tech Innovation
Intelligent Bio Solutions (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. Its Intelligent Fingerprinting Drug Testing Solution is currently being utilized across multiple industries, With recent FDA 510(k) submission in December of 2024 and entry into the US market planned for 2025, INBS is capitalizing on the rapidly growing drug screening products market.
Intelligent Bio Solutions News
Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market
Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k) submission with method comparison, usability, and interference testing
Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant
Patent strengthens competitive position in European drug screening market and reinforces Company’s European intellectual property protection NEW YORK, March 26, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the
Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry
Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S. market entry in 2026 Partnership on track to deliver annual production cost savings